1. Nebivolol protects against cyclophosphamide‐induced nephrotoxicity through modulation of oxidative stress, inflammation, and apoptosis. (15th February 2021) Authors: Wanas, Hanaa; El‐Shabrawy, Mohamed; Mishriki, Amal; Attia, Hisham; Emam, Mohamed; Aboulhoda, Basma Emad Journal: Clinical and experimental pharmacology and physiology Issue: Volume 48:Number 5(2021) Page Start: 811 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Prognostic factors for predicting severity and mortality in hospitalized COVID‐19 patients. Issue 3 (25th January 2022) Authors: Aljohani, Fahad Dakilallah; Khattab, Amin; Elbadawy, Hossein M.; Alhaddad, Aisha; Alahmadey, Ziab; Alahmadi, Yaser; Eltahir, Heba M.; Matar, Heba M. H.; Wanas, Hanaa Journal: Journal of clinical laboratory analysis Issue: Volume 36:Issue 3(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Protective effect of tolvaptan against cyclophosphamide‐induced nephrotoxicity in rat models. Issue 5 (30th September 2020) Authors: El‐Shabrawy, Mohamed; Mishriki, Amal; Attia, Hisham; Emad Aboulhoda, Basma; Emam, Mohamed; Wanas, Hanaa Journal: Pharmacology research & perspectives Issue: Volume 8:Issue 5(2020) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗